1
|
Du J, Shi LL, Jiang WW, Liu XA, Wu XH, Huang XX, Huo MW, Shi LZ, Dong J, Jiang X, Huang R, Cao QR, Zhang W. Crafting Docetaxel-Loaded Albumin Nanoparticles Through a Novel Thermal-Driven Self-Assembly/Microfluidic Combination Technology: Formulation, Process Optimization, Stability, and Bioavailability. Int J Nanomedicine 2024; 19:5071-5094. [PMID: 38846644 PMCID: PMC11155381 DOI: 10.2147/ijn.s457482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 05/16/2024] [Indexed: 06/09/2024] Open
Abstract
Background The commercial docetaxel (DTX) formulation causes severe side effects due to polysorbate 80 and ethanol. Novel surfactant-free nanoparticle (NP) systems are needed to improve bioavailability and reduce side effects. However, controlling the particle size and stability of NPs and improving the batch-to-batch variation are the major challenges. Methods DTX-loaded bovine serum albumin nanoparticles (DTX-BSA-NPs) were prepared by a novel thermal-driven self-assembly/microfluidic technology. Single-factor analysis and orthogonal test were conducted to obtain the optimal formulation of DTX-BSA-NPs in terms of particle size, encapsulation efficiency (EE), and drug loading (DL). The effects of oil/water flow rate and pump pressure on the particle size, EE, and DL were investigated to optimize the preparation process of DTX-BSA-NPs. The drug release, physicochemical properties, stability, and pharmacokinetics of NPs were evaluated. Results The optimized DTX-BSA-NPs were uniform, with a particle size of 118.30 nm, EE of 89.04%, and DL of 8.27%. They showed a sustained release of 70% over 96 hours and an increased stability. There were some interactions between the drug and excipients in DTX-BSA-NPs. The half-life, mean residence time, and area under the curve (AUC) of DTX-BSA-NPs increased, but plasma clearance decreased when compared with DTX. Conclusion The thermal-driven self-assembly/microfluidic combination method effectively produces BSA-based NPs that improve the bioavailability and stability of DTX, offering a promising alternative to traditional formulations.
Collapse
Affiliation(s)
- Juan Du
- Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People’s Republic of China
| | - Li-Li Shi
- College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China
| | - Wei-Wei Jiang
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Xue-Ai Liu
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Xin-Hong Wu
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Xiang-Xiang Huang
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Ming-Wei Huo
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Ling-Zhi Shi
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Jingjian Dong
- College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China
| | - Xiaohong Jiang
- College of Medicine, Jiaxing University, Jiaxing, People’s Republic of China
| | - Renyu Huang
- College of Social Science, Soochow University, Institute of Culture and Tourism Development, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Qing-Ri Cao
- College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, People’s Republic of China
| | - Wenzhou Zhang
- Department of Pharmacy, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, People’s Republic of China
| |
Collapse
|
2
|
Xiong Y, Xie L, Tang L, Xiao D, Shi W, Wang Y, Li Y, Han X, Ying X, Zheng Y. A liposomal etoposide with a sustained drug release effectively alleviated the therapy-related leukemia. Int J Pharm 2023; 646:123437. [PMID: 37741559 DOI: 10.1016/j.ijpharm.2023.123437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 09/12/2023] [Accepted: 09/21/2023] [Indexed: 09/25/2023]
Abstract
Etoposide (VP16) can induce therapy-related leukemia, which is reported to occur less frequently with a prolonged dose schedule. Therefore, we hypothesized that nanocarriers could decrease the VP16-induced leukemogenesis by reducing the rate of VP16 exposure via a sustained drug release. To test our hypothesis, the VP16-loaded liposome with a slow drug release behavior was constructed by encapsulating a rapidly-cleaved VP16-maleimide conjugate into liposomes using a glutathione-gradient loading method, and its toxicities and in vivo antitumor efficacy were compared with free VP16 in the LLC lung cancer xenograft. It was found that the repeated injection of free VP16 induced severe splenomegaly, lymphocytosis, and extensive lymphocyte infiltration in various tissues, indicating a sign of VP16 therapy-related leukemia. By contrast, the liposomal VP16 not only remarkably alleviated the syndrome of leukemogenesis, but also exhibited significantly enhanced antitumor activity as compared with free VP16 at the same dose. These results highlighted that the liposomal VP16 having a sustained drug release could effectively decrease the toxicity of leukemogenesis, which provided a new warranty to develop liposomal VP16 as a safe alternative to the commercial VP16 injection.
Collapse
Affiliation(s)
- Yan Xiong
- The Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, China
| | - Lei Xie
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China
| | - Lingfeng Tang
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China
| | - Danling Xiao
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China
| | - Wenhao Shi
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China
| | - Yang Wang
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China
| | - Yang Li
- Department of Pharmaceutics, College of Pharmacy, Chongqing Medical University, Chongqing 400016, China
| | - Xue Han
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China.
| | - Xue Ying
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China.
| | - Yaxin Zheng
- School of Pharmacy, Key Laboratory of Sichuan Province for Specific Structure of Small Molecule Drugs, Chengdu Medical College, Chengdu, China.
| |
Collapse
|
3
|
Kovshova T, Mantrov S, Boiko S, Malinovskaya J, Merkulova M, Osipova N, Moiseeva N, Akimov M, Dudina P, Senchikhin I, Ermolenko Y, Gelperina S. Co-delivery of paclitaxel and etoposide prodrug by human serum albumin and PLGA nanoparticles: synergistic cytotoxicity in brain tumour cells. J Microencapsul 2023; 40:246-262. [PMID: 36880479 DOI: 10.1080/02652048.2023.2188943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023]
Abstract
The aims of this study were to develop co-delivery systems of paclitaxel (PTX) and etoposide prodrug (4'-O-benzyloxycarbonyl-etoposide, ETP-cbz) based on non-cross-linked human serum albumin (HSA) and poly(lactide-co-glycolide) nanoparticles and to evaluate the synergistic potential of these drugs in vitro. The nanoformulations were prepared by the high-pressure homogenisation technique and characterised using DLS, TEM, SEM, AFM, HPLC, CZE, in-vitro release, and cytotoxicity in human and murine glioma cells. All nanoparticles had 90-150 nm in size and negative ζ-potentials. The Neuro2A cells were the most sensitive to both HSA- and PLGA-based co-delivery systems (IC50 0.024 µM and 0.053 µM, respectively). The drugs' synergistic effect (combination index < 0.9) was observed in the GL261 cells for both types of co-delivery formulations and in the Neuro2A cells for the HSA-based system. These nanodelivery systems may be useful to improve combination chemotherapy for brain tumour treatment. To our knowledge, this is the first report describing the non-cross-linked HSA-based co-delivery nanosuspension which was prepared using nab™ technology.
Collapse
Affiliation(s)
- Tatyana Kovshova
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Sergey Mantrov
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Svetlana Boiko
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Julia Malinovskaya
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Maria Merkulova
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Nadezhda Osipova
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Natalia Moiseeva
- N.N. Blokhin National Medical Research Center of Oncology, Moscow, Russia
| | - Mikhail Akimov
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| | - Polina Dudina
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia
| | - Ivan Senchikhin
- Frumkin Institute of Physical Chemistry and Electrochemistry, Russian Academy of Sciences, Moscow, Russia
| | - Yulia Ermolenko
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| | - Svetlana Gelperina
- D. Mendeleev University of Chemical Technology of Russia, Moscow, Russia
| |
Collapse
|
4
|
Insight into the in vivo fate of intravenous herpetrione amorphous nanosuspensions by aggregation-caused quenching probes. CHINESE CHEM LETT 2022. [DOI: 10.1016/j.cclet.2022.03.108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
5
|
Sheikh BA, Bhat BA, Alshehri B, Mir RA, Mir WR, Parry ZA, Mir MA. Nano-Drug Delivery Systems: Possible End to the Rising Threats of Tuberculosis. J Biomed Nanotechnol 2021; 17:2298-2318. [PMID: 34974855 DOI: 10.1166/jbn.2021.3201] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Tuberculosis (TB) is still one of the deadliest disease across the globe caused by Mycobacterium tuberculosis (Mtb). Mtb invades host macrophages and other immune cells, modifies their lysosome trafficking proteins, prevents phagolysosomes formation, and inhibits the TNF receptor-dependent apoptosis in macrophages and monocytes. Tuberculosis (TB) killed 1.4 million people worldwide in the year 2019. Despite the advancements in tuberculosis (TB) treatments, multidrugresistant tuberculosis (MDR-TB) remains a severe threat to human health. The complications are further compounded by the emergence of MDR/XDR strains and the failure of conventional drug regimens to eradicate the resistant bacterial strains. Thus, new therapeutic approaches aim to ensure cure without relapse, to prevent the occurrence of deaths and emergence of drug-resistant strains. In this context, this review article summarises the essential nanotechnology-related research outcomes in the treatment of tuberculosis (TB), including drug-susceptible and drug-resistant strains of Mtb. The novel anti-tuberculosis drug delivery systems are also being detailed. This article highlights recent advances in tuberculosis (TB) treatments, including the use of novel drug delivery technologies such as solid lipid nanoparticles, liposomes, polymeric micelles, nano-suspensions, nano-emulsion, niosomes, liposomes, polymeric nanoparticles and microparticles for the delivery of anti-TB drugs and hence eradication and control of both drug-susceptible as well as drug-resistant strains of Mtb.
Collapse
Affiliation(s)
- Bashir A Sheikh
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Basharat A Bhat
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Bader Alshehri
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Majmaah University KSA, Almajmaah, 11952, Saudi Arabia
| | - Rakeeb A Mir
- Department of Biotechnology, School of Biosciences and Biotechnology, BGSB University, Rajouri 185234, J&K, India
| | - Wajahat R Mir
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| | - Zahoor A Parry
- Clinical Microbiology PK/PD/Laboratory, Indian Institute of Integrated Medicine (IIIM)-Srinagar 190005, J&K, India
| | - Manzoor A Mir
- Department of Bio-Resources, School of Biological Sciences, University of Kashmir, Srinagar 190006, J&K, India
| |
Collapse
|
6
|
Ren Y, Feng Y, Xu K, Yue S, Yang T, Nie K, Xu M, Xu H, Xiong X, Körte F, Barbeck M, Zhang P, Liu L. Enhanced Bioavailability of Dihydrotanshinone I-Bovine Serum Albumin Nanoparticles for Stroke Therapy. Front Pharmacol 2021; 12:721988. [PMID: 34531747 PMCID: PMC8438562 DOI: 10.3389/fphar.2021.721988] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2021] [Accepted: 07/28/2021] [Indexed: 02/03/2023] Open
Abstract
Dihydrotanshinone I (DHT) is a natural component in Salvia miltiorrhiza and has been widely researched for its multiple bioactivities. However, poor solubility and biocompatibility of DHT limit its desirable application for clinical purposes. Herein, DHT was encapsulated with bovine serum albumin (BSA) to enhance bioavailability. Compared to free DHT, DHT-BSA NPs (nanoparticles) showed an improved solubility in normal saline and increased protection against hydrogen peroxide-induced oxidative damage in PC12 cells. In addition, DHT-BSA NPs administered by intravenous injection displayed a significant efficacy in the middle cerebral artery occlusion/reperfusion models, without any impact on the cerebral blood flow. In summary, DHT-BSA NPs show an enhanced bioavailability compared with free DHT and a successful penetration into the central nervous system for stroke therapy, demonstrating their application potential in cardio-cerebrovascular diseases.
Collapse
Affiliation(s)
- Yanru Ren
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Yicheng Feng
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Kunyao Xu
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Saisai Yue
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Tiantian Yang
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Kaili Nie
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Man Xu
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Haijun Xu
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Xin Xiong
- NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
| | - Fabian Körte
- NMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany
| | - Mike Barbeck
- Institute of Material Science and Technology, Technical University of Berlin, Berlin, Germany
| | - Peisen Zhang
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| | - Luo Liu
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China
| |
Collapse
|
7
|
Characterization and Applications of Colloidal Systems as Versatile Drug Delivery Carriers for Parenteral Formulations. Pharmaceuticals (Basel) 2021; 14:ph14020108. [PMID: 33573103 PMCID: PMC7911661 DOI: 10.3390/ph14020108] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2021] [Revised: 01/26/2021] [Accepted: 01/27/2021] [Indexed: 01/17/2023] Open
Abstract
Preparing a suitable formulation for parenteral administration is already a difficult task; this, coupled with poor water-soluble new chemical entity (NCE), complicates this situation even further. There are several methodologies available to enhance water solubility, but this alone does not entail successful formulation. Making a micro/nano emulsion with a suitable surfactant not only increases the drug solubility but also the cell membrane permeability. Thus, not only biopharmaceutic classification system (BCS)-II (low solubility compounds) but also BCS-III (low permeability) and BCS-IV drugs (low solubility and low permeability) can be further exploited. Those drug candidates otherwise will not move further in NCE evaluation or clinical trials. This succinct review article delves into various aspects of biphasic micro/nano emulsion systems for parenteral drug delivery including the structure of the biphasic colloidal systems, characterization parameters, stability issues, regulatory considerations, and applications in life sciences.
Collapse
|
8
|
Zhang LS, Yan LX, Gao S, Long H, Xi Z, Li LY, Zhang ZS. Self-assembling peptide-etoposide nanofibers for overcoming multidrug resistance. Chem Commun (Camb) 2020; 56:15321-15324. [PMID: 33205785 DOI: 10.1039/d0cc06387h] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We developed a new strategy to overcome the MDR of etoposide using self-assembling nanofibers. Compared with the original etoposide, the inhibitory activity of Nap-GFFpYK-etoposide1/2 against murine Lewis lung cancer or breast cancer cells was increased 10 times, and 20 times on these cells with artificially overexpressed MDR1. Our method to synthesize and separate etoposide isomers provides a new strategy for the modification of this drug.
Collapse
Affiliation(s)
- Li-Song Zhang
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, NanKai University, Tianjin 300350, China.
| | | | | | | | | | | | | |
Collapse
|
9
|
Quality by design (QbD) approach in processing polymeric nanoparticles loading anticancer drugs by high pressure homogenizer. Heliyon 2020; 6:e03846. [PMID: 32373744 PMCID: PMC7193322 DOI: 10.1016/j.heliyon.2020.e03846] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 04/11/2020] [Accepted: 04/21/2020] [Indexed: 01/04/2023] Open
Abstract
Polymeric nanoparticles prepared using high pressure homogenizer (HPH) present some unique challenges during manufacturing which can be better understood by application of quality by design (QbD) approaches. The present review highlights the ways to identify the critical material attributes which includes the anticancer drugs, polymers, surfactants, solvent system and dispersion system. A comprehensive understanding of the critical processing parameters like pressure and number of cycles during the working of HPH used in putting forward the critical quality attributes such as size, shape, surface charge or droplet stabilization. Such QbD approach will involve development of an effective control strategy for would ensure safe encapsulation of anticancer drugs for successful product development. Proper addressing of the issues related to scaling-up would lead to successful commercialization of the nano-sized formulations loaded with anticancer drugs.
Collapse
|
10
|
Yadav KS, Kale K. High Pressure Homogenizer in Pharmaceuticals: Understanding Its Critical Processing Parameters and Applications. J Pharm Innov 2019. [DOI: 10.1007/s12247-019-09413-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
|
11
|
Comparative Pharmacokinetics and Biodistribution of Etoposide in a Polymer Dosage Form and as Free Drug Substance. Pharm Chem J 2019. [DOI: 10.1007/s11094-019-01921-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Ahire E, Thakkar S, Darshanwad M, Misra M. Parenteral nanosuspensions: a brief review from solubility enhancement to more novel and specific applications. Acta Pharm Sin B 2018; 8:733-755. [PMID: 30245962 PMCID: PMC6146387 DOI: 10.1016/j.apsb.2018.07.011] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Revised: 04/20/2018] [Accepted: 06/26/2018] [Indexed: 02/01/2023] Open
Abstract
Advancements in in silico techniques of lead molecule selection have resulted in the failure of around 70% of new chemical entities (NCEs). Some of these molecules are getting rejected at final developmental stage resulting in wastage of money and resources. Unfavourable physicochemical properties affect ADME profile of any efficacious and potent molecule, which may ultimately lead to killing of NCE at final stage. Numerous techniques are being explored including nanocrystals for solubility enhancement purposes. Nanocrystals are the most successful and the ones which had a shorter gap between invention and subsequent commercialization of the first marketed product. Several nanocrystal-based products are commercially available and there is a paradigm shift in using approach from simply being solubility enhancement technique to more novel and specific applications. Some other aspects in relation to parenteral nanosuspensions are concentrations of surfactant to be used, scalability and in vivo fate. At present, there exists a wide gap due to poor understanding of these critical factors, which we have tried to address in this review. This review will focus on parenteral nanosuspensions, covering varied aspects especially stabilizers used, GRAS (Generally Recognized as Safe) status of stabilizers, scalability challenges, issues of physical and chemical stability, solidification techniques to combat stability problems and in vivo fate.
Collapse
Key Words
- ADME, absorption distribution metabolism elimination
- ASEs, aerosols solvent extractions
- AUC, area under curve
- BBB, blood–brain barrier
- BCS, Biopharmaceutical Classification System
- BDP, beclomethasone dipropionate
- CFC, critical flocculation concentration
- CLSM, confocal laser scanning microscopy
- CMC, critical micelle concentration
- DMSO, dimethyl sulfoxide
- EDI, estimated daily intake
- EHDA, electrohydrodynamic atomization
- EPAS, evaporative precipitation in aqueous solution
- EPR, enhanced permeability and retention
- FITC, fluorescein isothiocyanate
- GRAS, Generally Recognized as Safe
- HEC, hydroxyethylcellulose
- HFBII, class II hydrophobin
- HP-PTX/NC, hyaluronic acid-paclitaxel/nanocrystal
- HPC, hydroxypropyl cellulose
- HPH, high-pressure homogenization
- HPMC, hydroxypropyl methylcellulose
- IM, intramuscular
- IP, intraperitoneal
- IV, intravenous
- IVIVC, in vivo–in vitro correlation
- In vivo fate
- LD50, median lethal dose (50%)
- MDR, multidrug resistance effect
- NCE, new chemical entities
- Nanosuspension
- P-gp, permeation glycoprotein
- PEG, polyethylene glycol
- PTX, paclitaxel
- PVA, polyvinyl alcohol
- Parenteral
- QbD, quality by design
- SC, subcutaneous
- SEDS, solution enhanced dispersion by supercritical fluids
- SEM, scanning electron microscopy
- SFL, spray freezing into liquids
- Scalability
- Solidification
- Stabilizer
- TBA, tert-butanol
- TEM, transmission electron microscopy
- US FDA, United States Food and Drug Administration
- Vitamin E TPGS, d-α-tocopheryl polyethylene glycol 1000 succinate
Collapse
Affiliation(s)
| | | | | | - Manju Misra
- Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, Gujarat 380054, India
| |
Collapse
|
13
|
Elgohary MM, Helmy MW, Abdelfattah EZA, Ragab DM, Mortada SM, Fang JY, Elzoghby AO. Targeting sialic acid residues on lung cancer cells by inhalable boronic acid-decorated albumin nanocomposites for combined chemo/herbal therapy. J Control Release 2018; 285:230-243. [DOI: 10.1016/j.jconrel.2018.07.014] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2018] [Revised: 07/06/2018] [Accepted: 07/09/2018] [Indexed: 10/28/2022]
|
14
|
Elgohary MM, Helmy MW, Mortada SM, Elzoghby AO. Dual-targeted nano-in-nano albumin carriers enhance the efficacy of combined chemo/herbal therapy of lung cancer. Nanomedicine (Lond) 2018; 13:2221-2224. [DOI: 10.2217/nnm-2018-0097] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Aim: A Nano-in-Nano approach was exploited to facilitate incorporation of the chemotherapeutic drug etoposide (ETP) as nanosuspension, synergistically with berberine (BER) into hydrophilic albumin nanoparticles (HSA NPs).Methods: For maximal tumor targeting, HSA was modified with mannose and phenyl-boronic acid. Furthermore, different crosslinkers were investigated for sustained release of water soluble BER from HSA NPs. Results: The elaborated dual-targeted HSA NPs (216.2 nm) were spherical with high BER and ETP entrapment efficiency (69.5 and 87.6%, respectively) and loading (10.52 and 14.04%, respectively). The NPs exhibited sequential release pattern for both ETP and BER (51.55 and 34.33% over 72 h, respectively). Phenyl-boronic acid/mannose-HSA NPs demonstrated powerful cytotoxicity against A549 lung cancer cells (IC50: 12.4 μg/ml) correlated to enhanced cellular internalization. Dual-targeted NPs displayed 9.77-fold higher caspase-3 level and 3.5-fold lower VEGF level than positive control mice. Conclusion: Dual-targeted Nano-in-Nano albumin carriers could be beneficial for parenteral ETP/BER delivery to lung cancer.
Collapse
Affiliation(s)
- Mayada M Elgohary
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Maged W Helmy
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Pharmacology & Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt
| | - Sana M Mortada
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
| | - Ahmed O Elzoghby
- Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt
- Division of Engineering in Medicine, Department of Medicine, Brigham & Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
- Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA
| |
Collapse
|
15
|
Li Q, Chen F, Liu Y, Yu S, Gai X, Ye M, Yang X, Pan W. A novel albumin wrapped nanosuspension of meloxicam to improve inflammation-targeting effects. Int J Nanomedicine 2018; 13:4711-4725. [PMID: 30154656 PMCID: PMC6103556 DOI: 10.2147/ijn.s160714] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Background The objective of this study was to develop a more bio-available and safe nanosuspension of meloxicam (MX), which could dramatically improve inflammation targeting. Methods and results MX-loaded bovine serum albumin (BSA) nanosuspensions were prepared using acid–base neutralization in aqueous solution and the prepared nanosuspensions were characterized. The results obtained showed that the prepared nanosuspensions had a narrow size distribution with a mean particle size of 78.67±0.22 nm, a polydispersity index of 0.133±0.01, and a zeta potential of −11.87±0.91 mV. The prepared MX nanosuspensions were spherically wrapped by BSA with a smooth surface as shown by transmission electron microscopy. Stability studies showed that the nanosuspensions were physically stable at 4°C with a shelf life of at least 6 months. In the in vitro dissolution test, the MX-loaded BSA nanosuspension (MX-BSA-NS) exhibited sustained release. In addition, an in vivo pharmacokinetic study in rats following intravenous injection showed that the half-life (t1/2), mean residence time (MRT), and area under the concentration–time curve (AUC0–∞) of MX-BSA-NS was increased by 169.83%, 150.13%, and 148.80%, respectively, in comparison with MX conventional solution (MX solution). Furthermore, results from inflammation targeting studies showed that the concentration of MX increased significantly in inflamed tissues but was reduced in normal tissues compared with the MX solution group after injection of MX-BSA-NS. Conclusion The prepared MX-BSA-NS significantly increased the inflammation-targeting properties and bioavailability of MX, suggesting its potential as a promising formulation for the targeted drug delivery of MX in future clinical applications.
Collapse
Affiliation(s)
- Qi Li
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Fen Chen
- Key Laboratory of Ministry of Education for TCM Viscera-State Theory and Applications, Liaoning University of Traditional Chinese Medicine, Shenyang 110016, People's Republic of China
| | - Yun Liu
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Shihui Yu
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Xiumei Gai
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Mingzhu Ye
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Xinggang Yang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| | - Weisan Pan
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China, ;
| |
Collapse
|
16
|
Gao L, Xie C, Du Y, Wang X, Xuan E, Liu X, Zhao Y, Xu J, Luo L. Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants. Drug Deliv 2017; 24:765-774. [PMID: 28475414 PMCID: PMC8241189 DOI: 10.1080/10717544.2017.1321063] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Etoposide is widely used in the chemotherapy of a variety of malignancies. But the strong lipophilicity, poor bioavailability, and severe side effects of etoposide limit its clinical application. The aim of this study was to develop sustained-release etoposide-loaded implants and evaluate antitumor activity of the implants after intratumoral implantation. We prepared the implants containing etoposide, poly(L-lactid acid) and polyethylene glycol 4000 by the direct compression method. The implants were characterized regarding drug-excipient compatibility, content uniformity, morphology, sterility, in vitro, and in vivo release profiles. Then the antitumor activity of the implants was tested in xenograft model of A549 human non-small cell lung cancer. SEM images displayed smooth surface of the implant and indicated that etoposide was homogeneously dispersed in the polymeric matrix. The results of content uniformity met the requirements of the Chinese Pharmacopoeia. Both in vitro and in vivo release profiles of the implants were characterized by high burst release followed by sustained release of etoposide. Intratumoral implantation of etoposide-loaded implants could efficiently delay the tumor growth. Furthermore, increasing the dose of implants led to higher tumor suppression rate without adding systemic toxicity. These results indicated that etoposide-loaded implants have significant antitumor efficacy in xenograft model without dose-limiting side effects and they possess a strong potential to be used as an intratumoral chemotherapy option for lung cancer treatment.
Collapse
Affiliation(s)
- Li Gao
- a State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University , Nanjing , People's Republic of China.,b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Chuanqi Xie
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Yuzhi Du
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Xiaodong Wang
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Erkang Xuan
- c Laboratory of pharmaceutical research , Anhui Zhongren Science and Technology Co., Ltd , Hefei , People's Republic of China , and
| | - Xiuxiu Liu
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Yang Zhao
- d Department of Pathology , The Second People's Hospital of Hefei , Hefei , People's Republic of China
| | - Jianjian Xu
- b School of Biological and Medical Engineering, Hefei University of Technology , Hefei , People's Republic of China
| | - Lan Luo
- a State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University , Nanjing , People's Republic of China
| |
Collapse
|
17
|
Preparation and evaluation of BSA-based hydrosol nanoparticles cross-linked with genipin for oral administration of poorly water-soluble curcumin. Int J Biol Macromol 2017. [DOI: 10.1016/j.ijbiomac.2017.06.083] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
18
|
Wang W, Lei Y, Sui H, Zhang W, Zhu R, Feng J, Wang H. Fabrication and evaluation of nanoparticle-assembled BSA microparticles for enhanced liver delivery of glycyrrhetinic acid. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2016; 45:740-747. [DOI: 10.1080/21691401.2016.1193024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Wenping Wang
- School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China
- Ningxia Engineering and Technology Research Center for Modernization of Hui Medicine, Yinchuan, Ningxia, China
- Key Lab of Hui Ethnic Medicine Modernization, Ministry of Education, Yinchuan, Ningxia, China
| | - Yaya Lei
- School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China
| | - Hong Sui
- School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China
- Ningxia Engineering and Technology Research Center for Modernization of Hui Medicine, Yinchuan, Ningxia, China
- Key Lab of Hui Ethnic Medicine Modernization, Ministry of Education, Yinchuan, Ningxia, China
| | - Wenping Zhang
- Department of Pharmaceutics, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
| | - Rongyue Zhu
- School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China
| | - Jun Feng
- School of Pharmacy, Ningxia Medical University, Yinchuan, Ningxia, China
| | - Hong Wang
- Department of Pharmaceutics, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
| |
Collapse
|
19
|
Singh J, Garg T, Rath G, Goyal AK. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis – a critical review. Drug Deliv 2015; 23:1676-98. [DOI: 10.3109/10717544.2015.1074765] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Xie X, Yang Y, Yang Y, Zhang H, Li Y, Mei X. A photo-responsive peptide- and asparagine-glycine-arginine (NGR) peptide-mediated liposomal delivery system. Drug Deliv 2015; 23:2445-2456. [PMID: 25693640 DOI: 10.3109/10717544.2015.1008707] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
The conjugation of tunable peptides or materials with nanocarriers represents a promising approach for drug delivery to tumor cells. In this study, we report the development of a novel liposomal carrier system that exploits the cell surface binding synergism between photo-sensitive peptides (PSPs) and targeting ligands. The positive charges of the lysine residues on the cell-penetrating peptides (CPPs) were temporarily caged by the photolabile-protective groups (PG), thereby forming a PSP. Furthermore, this PSP enhances specific uptake into cancer cells after rapidly uncaging the PG via near-infrared (NIR) light illumination. In the circulatory system, the cell penetrability of PSP was hindered. In contrast, the asparagine-glycine-arginine (NGR) peptide moieties, selectively bind to CD13-positive tumors, were attached to the nanocarrier to facilitate the active accumulation of this liposomal carrier in tumor tissue. The dual-modified liposomes (PSP/NGR-L) were prepared by emulsification method, and the concentrations of DSPE-PEG2000-psCPP and DSPE-PEG5000-NGR in the liposomes were chosen to be 4% and 1% (molar ratio), respectively. The mean particle size of the PSP/NGR-L was about 95 nm, and the drug entrapment efficiency was more than 90%. Cellular uptake results demonstrated that the proposed PSP/NGR-L had an enhancement of cancer cell recognition and specific uptake. Furthermore, the PSP/NGR-L demonstrated a stronger antitumor efficacy in the HT-1080 tumor model in nude mice with the aid of NIR illumination.
Collapse
Affiliation(s)
- Xiangyang Xie
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China.,b Wuhan General Hospital of Guangzhou Military Command , Wuhan , China , and
| | - Yanfang Yang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China.,c Beijing Key Laboratory of Drug Delivery Technology and Novel Formulation , Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing , China
| | - Yang Yang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Hui Zhang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Ying Li
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Xingguo Mei
- a Beijing Institute of Pharmacology and Toxicology , Beijing , China
| |
Collapse
|